AeroVironment shares (AVAV.US) are gaining around 15% after the company announced a $500 million contract with the U.S. Army to supply counter-drone systems. The deal further strengthens positive sentiment following record fiscal fourth-quarter 2026 results released just a few days earlier. The company is currently growing not only through unmanned systems, but also through the rapidly expanding counter-drone defense segment. Management believes this area could become one of AeroVironment’s key growth drivers over the next several years.
Pentagon focuses on drone defense
The contract was awarded by the U.S. Army Contracting Command at Detroit Arsenal and is structured as a firm-fixed-price framework agreement. AeroVironment will provide commercial Counter-UAS systems and solutions designed to detect and neutralize small drones used on the modern battlefield.
Work will be carried out through June 2029, with funding allocated as subsequent orders are placed by the U.S. Army.
The contract announcement came just days after AeroVironment reported very strong financial results. In the fiscal fourth quarter of 2026, AeroVironment delivered:
- revenue of $641.6 million, up 133% year-over-year,
- adjusted EBITDA of $140.1 million,
- adjusted EBITDA margin of 22%,
- adjusted earnings per share of $1.84 versus $1.61 a year earlier.
The sharp revenue increase was partly driven by the acquisitions of BlueHalo and Empirical Systems Aerospace, although organic growth still reached around 31%.
Backlog continues to grow
At the end of the fiscal year, funded backlog increased to $1.2 billion from $726.6 million a year earlier.
Total bookings reached $2.7 billion, compared with roughly $2 billion in revenue, resulting in a book-to-bill ratio of 1.4.
This means the company is winning new contracts faster than it is converting them into revenue, improving visibility for future sales.
Counter-UAS could become the next growth pillar
Although AeroVironment is best known for its Switchblade loitering munitions, management is increasingly focused on the counter-drone systems segment.
In fiscal 2026, the Counter-UAS business generated approximately $200 million in revenue.
The company is currently developing three main solutions:
- Titan radio-frequency jamming systems,
- LOCUST directed-energy weapons,
- Freedom Eagle-1 kinetic interceptors designed to destroy incoming drones.
CEO Wahid Nawabi believes that within the next 3–5 years, the Counter-UAS segment could match the scale of the company’s current business or even become two to three times larger.
Guidance remains strong
Management expects fiscal 2027 revenue of $2.1 billion to $2.2 billion, implying roughly 10% growth year-over-year.
The company also highlights very strong demand for its military solutions, especially in unmanned systems and counter-drone technologies.
Market still sees risks as shares remain 50% below their highs
Despite the latest rally, AeroVironment remains one of the more expensive defense stocks. Shares trade at roughly 54 times the midpoint of management’s fiscal 2027 adjusted earnings guidance.
Some investors remain concerned about the high price paid for the BlueHalo acquisition, while elevated short interest may keep the stock vulnerable to higher volatility. At the same time, the record backlog, strong Counter-UAS growth, and additional contracts with the U.S. Department of Defense continue to support the company’s long-term outlook.
AeroVironment shares are still trading roughly 50% below their record highs, which took the stock close to $400 per share in 2025. From current levels, the stock remains around 10% below a key resistance area marked by the 200-day Exponential Moving Average (EMA200), shown by the red line. Key support is located around $140–150 per share, based on previous price reactions.

Source: xStation 5
Daily Summary: A sell-off with a spin-off
US OPEN: The market extends losses as investor concerns grow
Market Wrap: European indices decline amid US - Iran tensions📉 Semiconductors under pressure
Netflix disappoints Wall Street 🚩 Stock drops 9% after disappointing outlook
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.